SIGA Technologies Inc (SIGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SIGA Technologies Inc (SIGA) has a cash flow conversion efficiency ratio of 0.000x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.66 Million) by net assets ($151.62 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SIGA Technologies Inc market cap and net worth for the company's overall valuation and market capitalisation.
SIGA Technologies Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how SIGA Technologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SIGA Technologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SIGA Technologies Inc ranked by their cash flow conversion efficiency. Explore SIGA cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Millennial Potash Corp.
V:MLP
|
-0.041x |
|
Unique Optical Industrial Co Ltd
TWO:3441
|
0.045x |
|
SNS
KLSE:0259
|
0.114x |
|
INFINITT Healthcare Co. Ltd
KQ:071200
|
0.024x |
|
Agilyx AS
OL:AGLX
|
-0.077x |
|
Azkoyen
MC:AZK
|
0.141x |
|
Young Fast Optoelectronics Co Ltd
TW:3622
|
0.016x |
|
Solar A/S
CO:SOLAR-B
|
0.215x |
Annual Cash Flow Conversion Efficiency for SIGA Technologies Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of SIGA Technologies Inc from 1996 to 2025. View SIGA Technologies Inc (SIGA) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $198.82 Million | $43.47 Million | 0.219x | -3.23% |
| 2024-12-31 | $215.80 Million | $48.76 Million | 0.226x | -53.08% |
| 2023-12-31 | $196.86 Million | $94.80 Million | 0.482x | +96.92% |
| 2022-12-31 | $170.16 Million | $41.61 Million | 0.245x | +270.84% |
| 2021-12-31 | $174.31 Million | $11.49 Million | 0.066x | -88.03% |
| 2020-12-31 | $129.79 Million | $71.52 Million | 0.551x | +395.98% |
| 2019-12-31 | $97.78 Million | $-18.20 Million | -0.186x | -127.82% |
| 2018-12-31 | $102.91 Million | $68.87 Million | 0.669x | +2550.63% |
| 2017-12-31 | $-323.14 Million | $-8.16 Million | 0.025x | -93.72% |
| 2016-12-31 | $-287.42 Million | $-115.59 Million | 0.402x | +1129.66% |
| 2015-12-31 | $-284.43 Million | $11.11 Million | -0.039x | +32.08% |
| 2014-12-31 | $-246.50 Million | $14.18 Million | -0.058x | -101.67% |
| 2013-12-31 | $16.98 Million | $58.44 Million | 3.442x | +592.75% |
| 2012-12-31 | $28.95 Million | $-20.22 Million | -0.699x | -213.88% |
| 2011-12-31 | $41.69 Million | $25.57 Million | 0.613x | +168.40% |
| 2010-12-31 | $12.07 Million | $-10.83 Million | -0.897x | -11.06% |
| 2009-12-31 | $10.49 Million | $-8.47 Million | -0.808x | +82.56% |
| 2008-12-31 | $1.55 Million | $-7.20 Million | -4.630x | -344.34% |
| 2007-12-31 | $5.23 Million | $-5.45 Million | -1.042x | -70.97% |
| 2006-12-31 | $7.28 Million | $-4.44 Million | -0.609x | -41.42% |
| 2005-12-31 | $3.23 Million | $-1.39 Million | -0.431x | +59.82% |
| 2004-12-31 | $4.56 Million | $-4.89 Million | -1.073x | -11.66% |
| 2003-12-31 | $5.55 Million | $-5.33 Million | -0.961x | +21.18% |
| 2002-12-31 | $2.17 Million | $-2.65 Million | -1.219x | -46.58% |
| 2001-12-31 | $3.54 Million | $-2.94 Million | -0.831x | +80.48% |
| 2000-12-31 | $924.74K | $-3.94 Million | -4.259x | -202.25% |
| 1999-12-31 | $2.20 Million | $-3.10 Million | -1.409x | -67.89% |
| 1998-12-31 | $5.60 Million | $-4.70 Million | -0.839x | -456.03% |
| 1997-12-31 | $10.60 Million | $-1.60 Million | -0.151x | +97.12% |
| 1996-12-31 | $400.00K | $-2.10 Million | -5.250x | -- |
About SIGA Technologies Inc
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.